Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation (SARA)
Sponsor: Biosense Webster, Inc.
Listed as NCT00863213, this PHASE4 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Biosense Webster, Inc., it has been updated 6 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biosense Webster, Inc.
- Fundacio Clinic Barcelona
- Hospital Clinic of Barcelona
- Medtronic
For direct contact, visit the study record on ClinicalTrials.gov .